SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

NCT04937972 | Unknown Phase 2

• 1 other identifier: SHR-1701
• Study Type: interventional
• Target: 71
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the trial was to evaluate the efficacy and safety of SHR-1701 combined with fluzopar as a first-line treatment maintenance therapy for advanced lung squamous cell carcinoma. Patients with advanced or metastatic (stage IV) lung squamous cell carcinoma have not received systemic chemotherapy and have measurable lesions (RECIST 1.1) ECOG PS 0-1. The patient received SHR1701 +fluzoparib

Conditions

Non-Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

• PFS

  Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

  1 year

Secondary Outcomes (2)

• ORR

  1 year

• DCR

  1 year

Study Arms (1)

SHR-1701 Combined With fluzoparib

EXPERIMENTAL

Drug: SHR-1701 Combined With Fluazopalil

Interventions

SHR-1701 Combined With Fluazopalil DRUG

SHR-1701 +fluzoparib

SHR-1701 Combined With fluzoparib

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The age at the time of signing the informed consent form is 18-75 years old, both male and female;
• Advanced or metastatic lung squamous cell carcinoma confirmed by histology or cytology;
• Has not received systemic treatment for the recurrence or metastasis stage in the past. If you have received neoadjuvant or adjuvant chemotherapy/radiotherapy in the past, those who have relapsed or metastasized\> 6 months from the end of treatment can be included in the group.
• ECOG PS score: 0-1 points;
• According to the RECIST 1.1 standard, the patient must have at least one measurable lesion;
• The function of major organs is normal, that is, it meets the following standards: a) Routine blood examination (under 14 days without blood transfusion and no hematopoietic stimulating factor drugs for correction): hemoglobin (Hb) ≥90g/L; absolute neutrophil count (ANC) ) ≥1.5×109/L; platelet (PLT) ≥100×109/L; white blood cell count (WBC) ≥3.0×109/L; b) Biochemical examination: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ×Upper limit of normal (ULN); serum total bilirubin (TBIL)≤1.5×ULN; serum creatinine (Cr)≤1.5×ULN or creatinine clearance ≥50ml/min; c) coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT)≤1.5×ULN; d) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF)≥50%;
• Expected survival period ≥ 3 months; Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 3 months after the last administration of the study drug; for men, surgical sterilization should be performed Or agree to use appropriate methods of contraception during the observation period and within 3 months after the last administration of the study drug;
• The patient voluntarily participates and signs the informed consent form (or signed by the legal representative). It is expected to have good compliance and be able to cooperate with the research according to the requirements of the plan.

You may not qualify if:

• \) Untreated brain metastases (persons who have previously received treatment for brain metastases (radiotherapy or surgery), if the images have been confirmed to be stable for at least 4 weeks before randomization, and systemic hormone therapy has been discontinued (dose\>10mg/day prednisone or Other equivalent hormones), those without clinical symptoms can be included in the group);
• \) With meningeal metastasis, spinal cord compression, etc.;
• \) Patients with pleural effusion, pericardial effusion or ascites who need to be drained with clinical symptoms, or who have received drainage of serous cavity effusion for treatment purposes within 2 weeks before randomization;
• \) Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (hepatitis B, defined as hepatitis B virus surface antigen \[HBsAg\] test results are positive, HBV-DNA ≥ 500 IU/ml and abnormal liver function; hepatitis C is defined as hepatitis C antibody \[HCV-Ab\] positive, HCV-RNA higher than the detection limit of the analysis method and abnormal liver function) or combined hepatitis B and C co-infection ；
• \) Suffer from any active autoimmune disease or history of autoimmune disease (such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (hormone replacement) Can be included after treatment)); patients with childhood asthma have been completely relieved and no intervention is required after adulthood or vitiligo can be included, and patients who require medical intervention with bronchodilators cannot be included;
• \) Severe infection (such as intravenous infusion of antibiotics, antifungal or antiviral drugs required) within 2 weeks before the first administration, or unexplained fever \>38.5°C during the screening period/before the first administration;
• \) Arterial/venous thrombosis events that occurred within 6 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
• \) Persons with a history of significant clinical significance of cardiovascular disease, including but not limited to; (1) Congestive heart failure (NYHA grade\> 2); (2) Unstable angina pectoris; (3) 3 months before signing the ICF Myocardial infarction occurred within; (4) Any supraventricular arrhythmia or ventricular arrhythmia that requires treatment or intervention;
• \) Suffered from or accompanied with other systemic malignancies in the last 5 years, (except for cured skin basal cell carcinoma, cervical carcinoma in situ and ovarian cancer);
• \) Have received a preventive vaccine or attenuated vaccine within 4 weeks before the first administration;
• \) Those who are known to be allergic to any test drug or its excipients;
• \) Pregnant and lactating patients, and reproductive patients are unwilling to take effective contraceptive measures;
• \) Have a clear history of neurological or mental disorders, including epilepsy and dementia;
• \) Patients who are unable to swallow the study drug, such as chronic diarrhea (including but not limited to irritable bowel syndrome, Crohn's disease, ulcerative colitis) and intestinal obstruction and other factors that affect drug intake and absorption;

Sponsors & Collaborators

• Hunan Province Tumor Hospital: lead

Study Sites (1)

Hunan Cancer Hospital

Changsha, Hunan, 410013, China

RECRUITING

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Yongchang Zhang, MD

  Hunan Cancer Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yongchang Zhang, MD

CONTACT

+8613873123436; zhangyongchang@csu.edu.cn

Nong Yang, MD

CONTACT

+8613055193557; yangnong0217@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: HunanPTH

Study Record Dates

• First Submitted: June 18, 2021
• First Posted: June 24, 2021
• Study Start: July 1, 2021
• Primary Completion: December 1, 2024
• Study Completion: June 1, 2025
• Last Updated: December 29, 2023

Record last verified: 2023-12

Locations

CN (1)